论文部分内容阅读
心房颤动(房颤)是一种常见的心律失常,治疗较困难,临床上一直缺乏理想的治疗方法,目前针对房颤发生基质为靶点的新治疗方法日益受到关注。最近一些临床试验提示血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体拮抗剂(ARB)可在高血压、左室肥厚、充血性心力衰竭、电复律的患者中预防新发房颤的发生和房颤的复发,但这种作用的具体机制还未得到深入的探讨。一些实验性研究提示肾素-血管紧张素系统(RAS)可能在房颤的电重构和结构重构中起重要作用。现对RAS在房颤发生和发展中的作用及可能机制,以及ACEI和ARB在房颤预防中的作用和可能机制作了系统的综述。
Atrial fibrillation (atrial fibrillation) is a common arrhythmia, the treatment is more difficult, the clinical has been the lack of ideal treatment, the current target of atrial fibrillation as a new target for the treatment of increasingly attention. Recent clinical trials suggest that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may prevent new homes in patients with hypertension, left ventricular hypertrophy, congestive heart failure, and cardioversion The occurrence of fibrillation and the recurrence of atrial fibrillation, but the specific mechanism of this role has not been explored in depth. Some experimental studies suggest that the renin-angiotensin system (RAS) may play an important role in the electrical remodeling and remodeling of atrial fibrillation. Now the role of RAS in the occurrence and development of atrial fibrillation and possible mechanisms, and the role of ACEI and ARB in the prevention of atrial fibrillation and possible mechanisms for a systematic review.